Sameer Gadani

Sameer Gadani

Auto-generated profile, based on publicly available information

Sameer Gadani

Department of Interventional Radiology, Cleveland Clinic Foundation, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
SGSameer Gadani
Sameer Gadani
SPSasan Partovi
Sasan Partovi
ALAbraham Levitin
Abraham Levitin
NZNicholas Zerona
Nicholas Zerona
SSShreya Sengupta
Shreya Sengupta
CQCristiano Quintini
Cristiano Quintini
Narrative review of portal vein thrombosis in cirrhosis: pathophysiology, diagnosis, and management from an interventional radiology perspective Sameer Gadani, Sasan Partovi, Abraham Levitin, Nicholas Zerona, Shreya Sengupta, Giuseppe D’Amico, Teresa Diago Uso, K. V. Narayanan Menon, Cristiano Quintini

9 October 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SGSameer Gadani
Sameer Gadani
JCJirapa Chansangrat
Jirapa Chansangrat
BKBaljendra Kapoor
Baljendra Kapoor
AMAaron McBride
Aaron McBride
SPSasan Partovi
Sasan Partovi
ALAbraham Levitin
Abraham Levitin

13 May 2025 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
EKEmily Knott
Emily Knott
BKBaljendra Kapoor
Baljendra Kapoor
JCJirapa Chansangrat
Jirapa Chansangrat
SPSasan Partovi
Sasan Partovi
GOGregory Owendoff
Gregory Owendoff
SGSameer Gadani
Sameer Gadani

1 April 2023 in Seminars in Interventional Radiology
Verified
Journal Article
Closed access
PDF file
EKEmily A. Knott
Emily A. Knott
SPSasan Partovi
Sasan Partovi
AMAaron McBride
Aaron McBride
ALAbraham Levitin
Abraham Levitin
SGSameer Gadani
Sameer Gadani
Liver resection can be curative in a select group of patients with primary and secondary hepatobiliary malignancies.[1] For these patients, the size and function of the future liver remnant (FLR) must be carefully considered to limit the potential for posthepatectomy liver failure (PHLF), a predominant cause of mortality.[1] [2] [3] [4] Preoperative portal vein embolization (PVE) has been shown to increase the volume of the FLR, allowing more patients to become surgical candidates and improving postoperative outcomes.[1] [2] [5] [6] [7] PVE occludes the portal venous branches supplying the lobe of the liver to be resected and redirects blood flow toward the FLR, leading to compensatory hypertrophy.[2] [8] There is a risk of disease progression in the time period between PVE and the growth of adequate FLR.[9] Only 60 to 86% of eligible patients eventually undergo resection, with cancellation primarily due to inadequate volume of the FLR and disease progression.[7] [10] [11] [12] [13] [14] This has led to considerable interest in techniques that accelerate hypertrophy of the FLR.[15] [16] [17] [18] A new technique for achieving hypertrophy of the FLR has recently been proposed: liver venous deprivation (LVD), or concomitant embolization of both portal and hepatic veins.[18] [19] This method is thought to accelerate liver hypertrophy by increasing hepatocellular injury and preventing venous collateralization across the embolized and nonembolized lobes of the liver.[20] Various techniques (e.g., the use of different embolic agents), timelines (subsequent vs. simultaneous), and approaches (transhepatic vs. transjugular) have been proposed to achieve this goal.[17] [19] [21] [22] [23] The technique we use employs vascular plugs and N-butyl cyanoacrylate (NBCA) to simultaneously embolize the hepatic and portal veins (PVs) in a single setting.[18] In this article, we discuss the anatomical considerations, indications/contraindications, and rationale for LVD. Detailed description of the LVD procedure with supplemental illustrations and images in this article will provide thorough review of this procedure for the physicians performing this procedure. Article published online: 16 June 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

18 January 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
TTTisileli S. Tuifua
Tisileli S. Tuifua
BKBaljendra Kapoor
Baljendra Kapoor
SPSasan Partovi
Sasan Partovi
SSShetal N. Shah
Shetal N. Shah
JBJennifer A. Bullen
Jennifer A. Bullen
SGSameer Gadani
Sameer Gadani

28 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SGSameer Gadani
Sameer Gadani
ECEdwin Chou
Edwin Chou
JCJirapa Chansangrat
Jirapa Chansangrat
HSHashim Salar
Hashim Salar
BKBaljendra Kapoor
Baljendra Kapoor
Locoregional therapies are used across the hepatocellular carcinoma (HCC) treatment spectrum, including for curative treatment of small tumors, as bridging or downstaging therapy before liver transplant, for treatment of intermediate-stage disease, and as part of combination treatment with systemic therapy in selected patients. This narrative review summarizes recent developments in transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and percutaneous ablation techniques and separates estab-lished clinical advances from early investigational work. The strongest evidence supports personalized TARE dosimetry and radiation segmentectomy, selective TACE with re-assessment before repeat treatment, and image-guided thermal ablation with objective margin assessment. Phase 3 trials of TACE combined with antiangiogenic and immune checkpoint therapy demonstrated improved progression-free survival in selected patients with unresectable, nonmetastatic HCC, although the effect on overall survival and the optimal treatment sequence remain uncertain. Histotripsy, pulsed electric-field ablation, electrochemotherapy, cryoablation, high-intensity focused ultrasound, imageable or al-ternative radioembolic microspheres, new embolic agents, robotics, and artificial intel-ligence remain at different stages of clinical development. Most supporting data are de-rived from single-arm studies, retrospective cohort studies, trials in mixed liver-tumor populations, or studies in preclinical models. Treatment selection should account for tumor burden and location, liver function, portal hypertension, vascular invasion, transplant candidacy, available alternatives, local expertise, and patient preferences. Future studies should focus on durable local control, preservation of liver function, quality of life, transplant eligibility, overall survival, and cost.